Project description
Testing cancer drugs that target RANK receptor
Triple negative breast cancer (TNBC) is commonly diagnosed in women younger than age 40. It remains a clinical challenge due to the high rate of relapse, a propensity to form visceral metastasis and limited targeted therapies. The ERC-funded TargetRANK project will identify novel targeted therapies for the treatment of TNBC. It is based on the innovative idea of generating novel drugs targeting the RANK receptor – instead of its ligand RANKL, as well as a new panel of anti-RANK human antibodies – for research and diagnostic purposes. The most important benefits of TargetRANK stem from the unmet need to improve the treatment of TNBC patients, and the economic burden for public health systems generated by standard non-selected and ineffective cancer treatments.
Objective
Breast cancer is the most common malignancy among females in the western world, resulting in nearly half a million deaths annually, mainly due to metastatic disease. Triple negative breast cancer (TNBC) accounts for almost 15–20% of all breast cancers (300.000 women diagnosed worldwide per year) and is commonly diagnosed in women younger than age 40. TNBC remains a clinical challenge due to high rate of relapse, a propensity to form visceral metastasis and limited targeted therapies. Thus, there is an urgent need to identify novel targeted therapies for the treatment of the TNBC. TargetRANK is based on the innovative idea of generating novel drugs targeting RANK receptor – instead of its ligand RANKL – for the treatment of TNBC, as well as a new panel of anti-RANK human antibodies – for research and diagnostic purposes. Small molecule inhibitors generated during the project could plausibly be positioned as a novel targeted therapy for TNBC and anti-RANK antibodies commercialized for research applications due to the lack of specific antibodies on the market. The most important benefits of TargetRANK are based on the unmet need to improve the treatment of TNBC patients, and the economic burden for public health systems generated by standard non-selected and ineffective cancer treatments. In addition, if drugs against RANK prove to be efficient, TargetRANK derived assets could also clinically benefit most of the patients suffering bone metastasis that are currently treated with bone resorption drugs, denosumab and bisphosphonates. Although our products are aimed for breast cancer, they may be therapeutically relevant for other tumors expressing RANK as non-small cell lung cancer. RANK antibodies will allow to stratify patients that might benefit from RANK blocking molecules, improving the existing treatments for skeletal-related events and reducing the main complications associated with life-altering morbidity affecting several types of prevalent cancers.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2022-POC1
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
28029 Madrid
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.